Skip to main content
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. — Investor Relations & Filings

Ticker · GLUE ISIN · US61225M1027 US Manufacturing
Open in API
Filings indexed 324 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US GLUE

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops small molecule precision medicines known as molecular glue degraders (MGDs). The company's proprietary drug discovery platform is engineered to rationally design MGDs that leverage the body's natural protein disposal system to selectively eliminate disease-causing proteins. This approach targets proteins that have been historically considered "undruggable" or are inadequately addressed by existing therapies. By integrating expertise in chemistry, artificial intelligence, structural biology, and proteomics, Monte Rosa is advancing a pipeline of therapeutic candidates primarily for cancer and other serious diseases.

Recent filings

Filing Released Lang Actions
10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Regulatory Filings
2026-05-07 English
S-8 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form S-8 filing, which is a registration statement used by companies to register securities to be offered to employees under employee benefit plans. The text includes detailed tables calculating filing fees for newly registered securities under stock option and employee stock purchase plans, references to Rule 416 under the Securities Act, and specific share amounts and pricing. There is no indication that this is an annual report, earnings release, or any other financial report. Instead, it is a regulatory filing related to securities registration for employee benefit plans. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7,525 characters) and content confirm it is not a brief announcement but a substantive filing, yet it does not fit other categories better than RNS.
2026-03-18 English
10-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Annual Report FY 2025
2026-03-17 English
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Monte Rosa Therapeutics, Inc. It announces the financial results for the quarter ended December 31, 2025, and includes a press release as an exhibit. The text explicitly states that the information is a press release announcing quarterly financial results, which corresponds to an Earnings Release. The document length is 3586 characters, which is relatively short and typical for an earnings release announcement. The content is not a full quarterly report with detailed financial statements, so it is not an Interim/Quarterly Report (IR). It is also not a report publication announcement since it contains the actual press release text. Therefore, the correct classification is Earnings Release (ER).
2026-03-17 English
4 - MONTE ROSA THERAPEUTICS, INC. (0001826457) (Filer)
Director's Dealing
2026-03-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.